Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Oct 25, 2011

Premium

David Macdonald has been named CEO at Agendia. He replaces Bernhard Sixt, who led the Dutch diagnostics firm since its founding in 2003. Sixt will remain with Agendia in an "advisory capacity," Agendia said.

Macdonald has served as Agendia's chief operating officer since last year. He previously worked at Quest Diagnostics, Behring Diagnostics, and Novo Medical. Macdonald holds a BS in management and finance from Northeastern University and an MBA from Babson College.

Agendia also said that Colin Goddard has joined its supervisory board of directors. Goddard is CEO of Coferon.


GenomeQuest has appointed Heidi Rehm, Madhuri Hegde, and Shashikant Kulkarni to its clinical advisory board.

Rehm is a molecular geneticist and assistant professor of pathology at Harvard Medical School. Hegde is an associate professor at the Emory University School of Medicine Department of Human Genetics and scientific director of the Emory Genetics Laboratory. She has also played a role in the development of several molecular testing panels commercialized by Oxford Gene Technology (BAN 8/23/2011). Kulkarni is medical director of genomics and pathology services and medical director of cytogenomics and molecular pathology at Washington University School of Medicine.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.